Can a virtual conference feel real? Do scientists have a say in their benefactors’ business? And what does it take to get remdesivir in the U.S.?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Kate Sheridan joins us for a dispatch from this week’s BIO conference, a huge annual event that has been forced online by the coronavirus pandemic. Then, we discuss the strange situation brewing at the Chan Zuckerberg Initiative, where a bunch of scientists have signed an open letter decrying their benefactor’s other business, Facebook. Finally, STAT’s Eric Boodman calls in to talk about the lengths patients have to go to get remdesivir, Gilead Sciences’ treatment for Covid-19.
For more on what we cover, here’s the latest from BIO; here’s more on the Chan Zuckerberg revolt; here’s the story on getting access to remdesivir; and here’s the latest in STAT’s coronavirus coverage.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].